Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.

Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed.